Business Wire

IBSA

Share
The IBSA Class40 – the Craft That Will Take Alberto Bona to the Route Du Rhum – Was Launched in Trinité-Sur-Mer

Latest-generation Class40, “scow” bow, five months of production: the IBSA craft with which Alberto Bona will participate in the Route du Rhum in November was launched yesterday in La Trinité-Sur-Mer (Brittany, France). It’s the first project of the three-year program Sailing into the Future. Together that the ocean sailor started in early 2022, together with the Swiss pharmaceutical company.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220802005581/en/

Designed by Sam Manuard , one of the great French naval architects when it comes to ocean classes, the IBSA Class40 was built by the JPS Production shipyard. It’s a Mach 5 model, the latest evolution of Manuard’s Class40, and will be present at the start of the Route du Rhum as one of the most innovative and modern boats. Much attention will surely be drawn to the rounded bow, created with the aim of increasing performance when sailing downwind, but also the hull promises high performance, thanks to the shape of the water lines and appendages, designed to make it a fast all-rounder when reaching too. Distinctive is also the design of the cockpit, large and well protected: a choice that will allow the sailor to face navigation in the most comfortable and safe positions possible. “This boat perfectly reflects our approach to the program ”, summarised Alberto Bona . “It’s the result of the search for detail, of the improvement in every single aspect: we were looking for a fast hull, clearly at the limits of the box rule, reliable in all weather conditions and sufficiently innovative to make a difference ”.

The project Sailing into the Future. Together started from scratch last January with a partnership – that between IBSA and Alberto Bona – born on common grounds and values, with the aim of using sailing as a corporate communication vehicle towards the market and the nautical world. “Ingenuity, courage, innovation, responsibility are elements which unite us - explained Bona - for this reason we are facing together this challenge, which is clearly sporting but which also metaphorically represents the Company's history, philosophy and vision always turned towards the future, and is part of a path bringing IBSA ever closer to environmental and social sustainability, inclusion and integration. In this type of challenge, the solitary navigator stands out but, as in the industry, the commander exists as a function of his team. With IBSA, we first of all built a team ”.

As for the team , we start with Sidney Gavignet as a coach: the very experienced French navigator laid the foundations and objectives, with a strict rule: always be prepared, to foresee all aspects of the challenge, on land and at sea. “Sidney put us in a position to divide this great challenge into many small steps. A long roadmap of stages to be reached, training and testing in preparation for the start, since building a challenge like the Route du Rhum from scratch in seven months is extremely demanding ”. For the physical preparation part, Bona relied on Andrea Madaffari : he has been working with him for months on endurance and strength, as well as on the management of the energy peaks necessary during a regatta. “When sailing, one needs stamina and does a lot of pulling and hauling: you pull sheets and halyards, you need endurance and peak strength ”, explained Bona . “We are working on this, as well as on the aerobic part ”.

The choice of Sam Manuard as a designer was virtually natural ,” recalled Bona , and is based on a solid relationship dating back to the time of the Mini class, on the sharing of a design vision and on the innovations that Bona was looking for his IBSA Class40. On the sails front, Bona chose Remi Aubrum , whom he entrusted with the choice of innovative materials, compatible with the rigorous box rule of the Class40. The last operational entry is that of the Boat Captain, the Breton expert Pierre-Edouard Regaud .

In recent months we have all been working with the same philosophy, that of the goals to be achieved day by day. We are working on fatigue management, on finding the best solutions in all aspects of the project. It was a huge team effort, between us and IBSA , that led us to yesterday’s technical launch, said Bona .

In the afternoon, at 5 pm, the IBSA Class40 made on board a truck the short journey between the shipyard and the marina that will host it, which is located in front of “Casa IBSA”, the operational headquarters . Alberto Bona now has one month to set up the boat and to qualify, by sailing a thousand miles by the end of August. On September 9, the actual launch – the ceremony that will officially make the Class40 enter the IBSA world – will take place in La Trinité-sur-Mer . In mid-September, Bona will participate in the Malouine Lamotte regatta; then, he will transfer his operational base to Saint-Malo, from where the first regatta of the three-year program will start.

We will talk to sailing enthusiasts and to the entire IBSA world, ” explained Bona , who also underlines the existence of a comprehensive sustainability project, in common with IBSA : “Navigators are experts in circular economy; they live for long periods on the ocean, they replace fossil fuels with solar and wind energy, they recycle everything they can, they live in true harmony with the sea, that they help protect: this is a very important message that, together with IBSA, we wish to promote and share, using the solo oceanic challenge as a great metaphor of what can and must be done for the environment ”.

In its program associated with sailing, IBSA is also committed to inclusiveness: in fact, the inclusive sailing project involving the Associazione Velabili based at the Circolo Velico Lago di Lugano (Switzerland), the Société des Régates d’Antibes (France) and the Yacht Club Punta Ala (Italy) has also been activated. The project aims to support inclusive sailing by promoting initiatives involving people with disabilities in experiences in contact with the sea and the sailing world, and consists in supporting a team of disabled sailors in participating in the Special Olympics World Games of 2023 and in the purchase of Hansa 303 boats for the Clubs of Punta Ala and Antibes.

IBSA

IBSA (Institut Biochimique SA ) is a Swiss multinational pharmaceutical Company, founded in 1945 in Lugano. Today, its products are present in over 90 Countries on 5 continents, through the Company’s 17 subsidiaries located in Europe, China, and the United States. The company has a consolidated turnover of 800 million CHF, and employs over 2,000 people between headquarters, subsidiaries and production sites. IBSA holds 90 families of approved patents, plus others under development, as well as a vast portfolio of products, covering 10 therapeutic areas: reproductive medicine, endocrinology, pain and inflammation, osteoarticular, aesthetic medicine, dermatology, uro-gynaecology, cardiometabolic, respiratory, consumer health. It is also one of the largest operators worldwide in the area of reproductive medicine, and one of the world’s leaders in hyaluronic acid-based products. IBSA has based its philosophy on four pillars: Person, Innovation, Quality and Responsibility.

Link:

ClickThru

Social Media:

https://www.facebook.com/ibsapharma

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Compass Pathways Announces FDA Acceptance of IND Application for PTSD and Hosts Webinar on PTSD and TRD7.1.2026 12:30:00 CET | Press release

FDA Accepts Investigational New Drug (IND) Application for COMP360 for the treatment of post-traumatic stress disorder (PTSD), enabling initiation of late-stage trialCompass continues to advance commercial preparations to be launch-ready by the end of the year for COMP360 for treatment-resistant depression (TRD)Management will host webinar with KOL and industry leaders to discuss PTSD clinical trial and commercial preparations for TRD from 10:00-11:30 am ET on January 7th Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for COMP360, enabling the initiation of a late-stage clinical trial in patients with PTSD. Compass management, along with KOL and industry leaders, will host a webinar today to discuss the company’s clinical trial plans for PTSD, as well as commercial preparations f

Stallergenes Greer Expands Venom Immunotherapy Production Capacity With Acquisition of Entomon s.r.l.7.1.2026 11:07:00 CET | Press release

Stallergenes Greer, a global leader in allergy therapeutics, today announced that it has entered into an agreement to acquire Entomon s.r.l., an Italian company specialising in the production of certified stinging-insect venom extracts, notably of the Hymenoptera order, used for the manufacture of diagnostic preparations and Venom Immunotherapy (VIT). The transaction is expected to close by the end of January. Entomon, currently recognised as the only company in Europe capable of extracting pure venom from Hymenoptera insects, produces pharmaceutical-grade insect venom using proprietary techniques (Entomon Capillary Extracted Venom®) for medical use. Through this acquisition, Stallergenes Greer bolsters its venom manufacturing capabilities and supply of raw materials for life-saving VIT treatments, whilst safeguarding patient care continuity. Hymenoptera venom allergy is the most common trigger of severe anaphylaxis in adults1. According to the EAACI guidelines on venom immunotherapy,

ARIS Announces New CEO to Lead Agentic AI-led Strategy7.1.2026 10:00:00 CET | Press release

CEO Appointment ARIS, a global leader in process intelligence and transformation software, today announced the appointment of Guillaume Bacuvier as Chief Executive Officer. Guillaume will lead ARIS through its next phase of growth as a fully standalone company, accelerating its evolution from a market leader in Process Intelligence into a foundational platform for enterprises deploying and governing Agentic AI. Guillaume brings deep international leadership experience across technology, data, and software-enabled businesses, with a proven track record of scaling global platforms and leading complex organisations. After starting as a strategic consultant at Booz Allen Hamilton, Guillaume spent over a decade at Google, rising to Vice President in EMEA where he built and scaled some of Google’s largest data-driven businesses in Europe and held P&L responsibility across multiple countries. In the last decade, Guillaume has served as CEO of multi-continent, data-centric companies including

I Squared Capital Acquires Ramudden Global, a Leader in Traffic Management and Infrastructure Safety7.1.2026 09:00:00 CET | Press release

Acquisition will accelerate Ramudden’s ambitious growth plan across North America and Europe supported by strong infrastructure spending tailwinds I Squared Capital, a leading global infrastructure investment manager, today announced that, through its flagship fund, it has agreed to acquire Ramudden Global, from funds advised by Triton Partners (“Triton”), a leading European mid-market sector-specialist investor. Ramudden Global is a leading international provider of traffic management and infrastructure safety services supporting the maintenance and upgrade of essential transport and utility networks. The company operates more than 190 depots across 13 countries in Europe and North America delivering mission-critical services that help to ensure safety, regulatory compliance and continuity of service across road, utility and broader infrastructure works. This investment underscores I Squared Capital’s commitment to investing in essential, regulated, infrastructure businesses that unde

RoslinCT and BOOST Pharma Announce Strategic Manufacturing Agreement to Advance Cell Therapy for Infants with Osteogenesis Imperfecta7.1.2026 09:00:00 CET | Press release

RoslinCT, a global contract development and manufacturing organization (CDMO) specializing in advanced cell therapies, and BOOST Pharma, a clinical-stage biotechnology company developing first-in-class cell therapies for rare paediatric skeletal diseases, today announced a strategic manufacturing partnership to support the development of BOOST Pharma’s cell therapy, BT-101, for the treatment of infants with Osteogenesis Imperfecta (OI), also known as brittle bone disease. Under the service agreement, BOOST Pharma has transferred its manufacturing process to RoslinCT’s state-of-the-art facilities in Edinburgh, Scotland. The partnership will progress toward GMP manufacturing of starting materials and clinical drug product, supporting Phase III clinical development of BT-101. The therapy is an allogeneic mesenchymal stem cell (MSC) product designed to address the underlying cause of OI at the earliest stages of life. BOOST Pharma was founded on pioneering science originating from Karolins

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye